Maiwei Bioscience (688062.SH): 9MW5211 injection clinical trial application approved by FDA.

Zhtng Cijng APP news, Maiwei Biological (688062.SH) announced that the company has received a "Study May Proceed Notification" issued by the Food and Drug Administration (FDA) of the United States. The clinical trial application for 9MW5211 injection for the treatment of inflammatory bowel disease (IBD) has officially obtained FDA approval. At the same time, its clinical trial applications for IBD, multiple sclerosis (MS), and other indications have been accepted by the National Medical Products Administration. The company is also actively advancing the clinical trial application work for other indications.